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A B S T R A C T
The role of reactive oxygen species (ROS) in smooth muscle contraction is poorly understood. We hypothesised
that G-protein coupled receptor (GPCR) activation and hypoxia induce Rho-kinase activity and contraction in rat
intra-pulmonary artery (IPA) via stimulation of ROS production and subsequent Src-family kinase (SrcFK) ac-
tivation.
The T-type prostanoid receptor agonist U46619 induced ROS production in pulmonary artery smooth muscle
cells (PASMC). U46619 also induced c-Src cysteine oxidation, SrcFK auto-phosphorylation, MYPT-1 and MLC20
phosphorylation and contraction in IPA, and all these responses were inhibited by antioxidants (ebselen,
Tempol). Contraction and SrcFK/MYPT-1/MLC20 phosphorylations were also inhibited by combined superoxide
dismutase and catalase, or by the SrcFK antagonist PP2, while contraction and MYPT-1/MLC20 phosphorylations
were inhibited by the Rho guanine nucleotide exchange factor (RhoGEF) inhibitor Y16. H2O2 and the super-
oxide-generating quinoledione LY83583 both induced c-Src oxidation, SrcFK auto-phosphorylation and con-
traction in IPA. LY83583 and H2O2-induced contractions were inhibited by PP2, while LY83583-induced con-
traction was also inhibited by antioxidants and Y16. SrcFK auto-phosphorylation and MYPT-1/MLC20
phosphorylation was also induced by hypoxia in IPA and this was blocked by mitochondrial inhibitors rotenone
and myxothiazol. In live PASMC, sub-cellular translocation of RhoA and the RhoGEF ARHGEF1 was triggered by
both U46619 and LY83583 and this translocation was blocked by antioxidants and PP2. RhoA translocation was
also inhibited by an ARHGEF1 siRNA. U46619 enhanced ROS-dependent co-immunoprecipitation of ARHGEF1
with c-Src.
Our results demonstrate a link between GPCR-induced cytosolic ROS or hypoxia-induced mitochondrial ROS
and SrcFK activity, Rho-kinase activity and contraction. ROS and SrcFK activate RhoA via ARHGEF1.
1. Introduction
Reactive oxygen species (ROS), previously thought to occur solely as
damaging bi-products of metabolism, are now recognised as bona ﬁde
second messengers in normal cellular function, being produced in re-
sponse to multiple stimuli, including G-protein-coupled receptor
(GPCR) agonists and hypoxia [1,2], presumably exerting their eﬀects
through reversible oxidation of speciﬁc target proteins, primarily on
cysteine residues [3–5]. Normally, the production and degradation of
ROS is tightly controlled by cytosolic or membrane-bound oxidor-
eductase enzymes, antioxidant enzymes and cellular redox buﬀers
[6,7], but in cardiovascular disease this control is lost, resulting in
oxidative stress [8]. GPCR induce vascular ROS production primarily
via NADPH oxidase [1,7], while in intra-pulmonary arteries (IPA),
hypoxia does so via the mitochondrial electron transport chain (com-
plex III), an essential step in hypoxic pulmonary vasoconstriction
[2,9,10]. Most contractile stimuli, including GPCR and hypoxia, exert
their eﬀects on smooth muscle cross-bridge cycling via a combination of
raised [Ca2+]i and inhibition of myosin light-chain phosphatase
[11–13], the latter being dependent on activation of Rho-kinase [14].
Applied exogenously, both superoxide (O2∙-) and its dismutation pro-
duct H2O2 have contractile eﬀects in pulmonary artery, but previous
work from our laboratory suggests that exogenous H2O2 primarily does
so via activation of PKC and elevation of [Ca2+]i, while artiﬁcially
induced cytosolic superoxide primarily activates Rho-kinase [15,16].
The role of endogenous ROS in Rho-kinase activation by GPCR or
hypoxia remains to be fully characterised because the signalling
pathway(s) through which ROS may activate Rho-kinase are unclear.
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Regardless of the initial stimulus, Rho-kinase activity usually requires
prior activation of monomeric G-proteins of the Rho family (including
RhoA), which in turn normally requires prior activation of guanine
nucleotide exchange factors selective for the Rho family of G-proteins
(RhoGEFs) [17]. Thus, either RhoA itself is directly ROS-sensitive [18]
or RhoGEF activation may be triggered by ROS independently of the
canonical G12/13 interaction [19,20].
Increased Rho-kinase activity contributes to acute hypoxic pul-
monary vasoconstriction [11,12], as well as elevated pulmonary artery
pressure in chronic hypoxia-induced pulmonary hypertension [21], but
how this increased activity is mediated remains unclear. Non-receptor
tyrosine kinases contribute to aberrant migratory and proliferative re-
sponses in oxidative stress-induced vascular remodelling [22,23], but
are also involved in normal contractile function in vascular smooth
muscle. For example, we showed that in IPA both GPCR-induced and
hypoxia-induced Rho-kinase activity and contraction was dependent on
prior activation of Src-family kinases (SrcFK) [11,24]. In non-muscle
cells, c-Src has been shown to be directly ROS-sensitive, with cysteine
oxidation enhancing its activity [25], though it may also be activated
indirectly through oxidative inhibition of its negative regulators, such
as c-Src kinase or speciﬁc tyrosine phosphatases (reviewed in [4,25]). It
has not been determined whether SrcFK are ROS-sensitive in IPA, nor
whether ROS- and/or SrcFK-mediated activation of RhoA/Rho-kinase
occurs as part of the same signalling pathway in response to GPCR or
hypoxia, but it is possible that SrcFK act as intermediaries between ROS
and RhoA/Rho-kinase. We therefore hypothesised that SrcFK act as key
mediators of ROS signalling in IPA, contributing to GPCR and hypoxia-
induced RhoA/Rho-kinase activity and contraction. We also examined
the role of ARHGEF1, an RGS-domain containing RhoGEF that has
previously been shown to be activated by tyrosine phosphorylation
[26].
2. Methods
2.1. Tissue and cell culture
This study conforms with UK Home Oﬃce regulations and Directive
2010/63/EU of the European Parliament. Adult male Wistar rats were
killed by lethal overdose of pentobarbital (~50 mg/kg i.p.). The lungs
were excised and placed in cold physiological saline solution (PSS,
composition in mM: 118NaCl, 24 NaHCO3, 1 MgSO4, 4 KCL, 5.56 D-
glucose, 0.434 NaH2PO4, 1.8 CaCl2, pH 7.4). Small intra-pulmonary
arteries (IPA; 200–500 µm i.d.) were dissected free of surrounding
parenchyma and either used for protein extraction and immunoblot-
ting, mounted on a myograph for measurement of contractile force, or
used for preparation of cultured pulmonary artery smooth muscle cells
(PASMC). PASMC were dispersed by enzymatic digestion (collagenase
type XI, papain, trypsin inhibitor), grown to passage 3–4 in DMEM and
serum-starved for 24 h prior to use. Each batch of cells was veriﬁed as
smooth muscle by immunostaining for smooth muscle α-actin, calponin
and desmin, as shown previously [1].
2.2. Contractile force measurement
IPA rings were mounted on a Mulvany-Halpern wire myograph
(DMT.dk) bathed in PSS and gassed with 95% air/5% CO2 (pH 7.4) at
37 °C. Vessels were stretched and pre-conditioned by stimulation with
repeated exposures to 80 mmol/l K+ PSS (KPSS, equimolar substitution
for NaCl), with resting tone being set at 1–3 mN, as previously de-
scribed [24]. Experiments were performed after ~30 min to allow for
stabilization. Tension was recorded using Acquisition Engine software
(Cairn Research Ltd, Faversham, UK).
2.3. Immuno-precipitation (IP) and Western blot (WB)
Following isolation and treatment with U46619 under normoxic
conditions (5% CO2/95% air) or hypoxic conditions (1% O2/5% CO2,
94% N2), IPA tissue samples were snap frozen in liquid nitrogen,
homogenised and protein extracted for IP and/or SDS-PAGE and
Western blot. For IP followed by WB, protein was extracted in TRIS-
buﬀered saline with triton (1%), whereas for immediate WB, protein
was extracted in TRIS-buﬀered saline with SDS (5%). IP was performed
using the Pierce™ Crosslink Magnetic IP/Co-IP Kit (8805) according to
the manufacturer instructions. Brieﬂy, lysates were incubated with anti-
c-Src antibody (1:20, Cell Signalling) and then covalently bound to
protein A/G Magnetic Beads (Pierce) overnight at 4 °C. Following ap-
propriate washing steps and elution, immuno-precipitates were re-sus-
pended in TRIS-SDS sample buﬀer.
For SDS-PAGE, gel total protein loading was normalised by BCA
assay. Membranes were blocked for 1hr at room temperature with 5%
skimmed milk in TBS-buﬀered saline with 0.05% Tween (TBS-T) then
probed with primary antibodies overnight at 4 °C (in 5% milk/TBS-T).
Dilutions were optimised for each primary antibody, typically 1:1000,
followed by horseradish peroxidase-conjugated secondary antibodies
for 1hr at room temperature (1:3000 in 5% milk/TBS-T). Membranes
were ﬁrst probed with anti-phospho-antibodies, then stripped for 1hr
(Pierce stripping buﬀer), re-blocked and re-probed with anti-total an-
tibodies. Protein bands were visualised using either SuperSignal West
Femto chemiluminescent substrate (Thermo Scientiﬁc) or ECL Prime
(Amersham, GE heatlthcare) in a Biorad ChemiDoc XRS+ Gel Imaging
System. Band intensity was expressed as a ratio of phospho/total for
each protein band of interest, and for each treated sample these ratios
were then expressed as a percentage of the control (untreated) samples
run on the same gel. Each control value was taken as the average of 2–3
identically treated samples on each gel.
2.4. ROS measurement
PASMC were seeded into 96-well plates, grown to 80–90% con-
ﬂuence and serum-starved for 24hrs. Cell were then incubated with the
luminol-derived superoxide probe 8-amino-5-chloro-7-phenylpyrido
[3,4-d]pyridazine-1,4-(2 H,3 H)-dione (L-012, 50 µM, Wako Pure
Chemical Industries) [27], in PBS at 37 °C. We also used an alternative
chemi-luminescence ROS probe (ROS-Glo™, Promega) [28] to measure
H2O2 production in IPA. Changes in luminescence induced by acute
drug treatments were detected using a Promega GloMax Multi+ plate
reader. Background measurements using ROS probe plus drug, but in
the absence of cells/tissue, were subtracted from all equivalent test
readings in the presence of cells/tissue. Each ﬁnal value for each
treatment for each batch of cells was the average of measurements from
at least 8 identically treated wells in each plate.
2.5. c-Src oxidation assay
Reversible oxidation of c-Src cysteine residues in response to acute
treatment with U46619 or exogenous ROS was determined using the
semi-quantitative PEG-switch method [29]. Brieﬂy, this involves in-
cubating IPA lysates with maleimide (100 mM, 25 min, 50 °C) to al-
kylate reduced cysteine residues. Then, following reduction of re-
versibly oxidised cysteines with dithiothreitol (DTT, 200 mM, 30 min,
RT°C) and desalting to remove maleimide and DTT (Zeba Spin desalting
columns, Thermo Scientiﬁc), lysates are incubated with poly-
ethyleneglycol 5000-tagged maleimide (PEG-maleimide, 10 mM, 2 h,
RT°C), to alkylate remaining reduced cysteine residues. When sub-
jecting the lysate to SDS-PAGE and probing for c-Src by Western blot,
reversible oxidation is indicated by separation of c-Src into two or more
bands due to oxidised cysteine pegylation increasing the protein mo-
lecular weight by multiples of 5KDa.
2.6. cDNA cloning, siRNA design and cell transfection
Rat RhoA cDNA was cloned into PCR2.1-TOPO® TA vector
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(Invitrogen Life Technologies, UK) by PCR using reverse transcribed
RNA that was obtained from PASMCs, whereas rat ARHGEF1 cDNA was
obtained from Source Bioscience UK Ltd. These were then used as
templates for cloning into pcDNA™6.2/C-EmGFP/TOPO® vector
(Invitrogen Life Technologies, UK). Oligonucleotide primers were de-
signed in accordance with the manual and using sequences form the
GenBank® database (RhoA accession no. BC061732; ARHGEF1 acces-
sion no. BC091218) as follows: Rat RhoA (forward):
GTTATGGCTGCCATCAGGAAGAAACTGG-3′, Rat RhoA (reverse): 5′-
CAAGATGAGGCACCCCGACT-3′, Rat ARHGEF1 (forward): 5′-
GAGATGGGAGAAGTCGCCGGAGGGGC-3′, Rat ARHGEF1 (reverse): 5′-
TGAAAGGCCTGTCTGAGCAGAGCGC-3′. The stop codon is in-
tentionally missed in the reverse primer to allow for fusion of the
EmGFP sequence that is present in the vector. The TOPO® TA tech-
nology will result in cloning of PCR products in both forward and re-
verse orientations, therefore clones were initially checked for the cor-
rect orientation using restriction endonuclease digestion and gel
electrophoresis. These were then fully checked by sequencing (Source
BioScience UK Limited) for selection. The rat ARHGEF1 siRNA was
designed as described previously [11,30]. The 19 nucleotide target
sequence (position 389–407, GenBank accession no. BC091218) was
synthesized into 64–65 mer oligonucleotides with BamHI/HindIII
overhangs (Sigma) and cloned into the expression vector pSilencer 3.0-
H1 (Ambion Inc.). All clones were puriﬁed (EndoFree Plasmid Maxi Kit,
Qiagen Ltd) and sequenced (Source BioScience UK Limited). A control
siRNA was designed based on a scrambled version of the ARHGEF1
target sequence.
Transfection was carried out in detached conﬂuent PASMCs by
electroporation using Amaxa™ Basic Nucleofector™ Kit for Primary
Smooth Muscle Cells (LONZA) and a Nucleofector™ 2b Device (Lonza).
Transfected cells were re-suspended in DMEM, seeded onto 19 mm
glass coverslips (VWR international), grown to ~50% conﬂuence and
serum-starved for 24 h. In each batch of cells transfected with
ARHGEF1 siRNA, eﬃcient knock-down of ARHGEF1 protein was con-
ﬁrmed by Western Blot (78±3% reduction vs. GAPDH, n=3 trans-
fections).
2.7. Cell imaging and quantiﬁcation
Coverslips were mounted onto a Zeiss Axiovert 200 Microscope and
cells visualised using BD™ CARV II Confocal Imager under X40 mag-
niﬁcation, bathed in PSS/5% CO2 at 37 °C. When illuminated with UV/
blue light (~390 nm). Successfully transfected cells were identiﬁed by
bright green ﬂuorescence. To minimise EmGFP bleaching, illumination
was limited to regular but brief (65 ms) shutter openings: typically once
every 2 s during agonist stimulation, but less frequent during rest per-
iods. During each illumination, images were captured by MetaFluor v.7
software (Molecular Devices). Regional and temporal changes in
ﬂuorescence in response to drug treatments were quantiﬁed using
ImageJ software (rsb.info.nih.gov).
2.8. Pharmacological agents, antioxidants and antibodies
The Src-family kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-
butyl)pyrazolo[3,4-d]pyrimidine (PP2), the antioxidants ebselen and
hydroxy-tempo (Tempol), the intracellular superoxide generator 6-
anilo-5,8-quinoledione (LY83583) and the thromboxane A2 mimetic
U46619 were all obtained from Merck Millipore. Superoxide dismutase
(SOD), catalase, maleimide, polyethyleneglycol maleimide 5000, di-
thiothreitol, the nitric oxide synthase inhibitor L-nitro-arginine methyl-
ester (L-NAME) and the inhibitor of RGS-domain containing RhoGEFs
(Y16) were obtained from Sigma. Anti-Src, anti-phospho-Src family
kinases (Tyr416), anti-MLC20, anti-phospho-MLC20 (Ser19), anti-
MYPT1, anti-ARHGEF1, anti-phospho-tyrosine (PY100) and anti-
GAPDH were all obtained from Cell Signalling (UK). Anti-phospho-
MYPT1 (Thr850) was from Upstate (UK). Anti-mouse IgG and anti-
rabbit IgG were from Sigma.
2.9. Statistical analysis
Statistical analysis was performed using SigmaPlot (Systat Software
Inc.). Two group comparisons were by paired or un-paired t-test where
appropriate. 1 factor or 2 factor multiple group comparisons were by 1-
way or 2-way ANOVA respectively, with appropriate post-tests. Unless
otherwise stated, n is the number of animals or cell lines derived from
individual animals. All values are expressed as mean± SEM.
3. Results
3.1. Endogenous ROS and SrcFK contribute to U46619-induced contraction
To determine the contribution of endogenous ROS to agonist-in-
duced contraction, we examined the eﬀects of the two structurally
dissimilar non-selective antioxidants ebselen and Tempol [31,32] on
contractile responses induced by the thromboxane mimetic U46619 in
IPA. 100 nM U46619 produced submaximal contractions equivalent to
50–75% of KPSS. Both inhibitors induced concentration-dependent re-
laxation (30–40% relaxation, Fig. 1A-B). As shown previously with
another TP receptor agonist PGF2α [24], U46619-induced contraction
was also sensitive to inhibition by the SrcFK antagonist PP2, which
induced concentration-dependent relaxation (~40% relaxation,
Fig. 1C). In order to eliminate the role of nitric oxide in the eﬀects of
antioxidants and PP2 on U46619-induced contraction, these experi-
ments were repeated in the presence of 300 µM L-NAME. Under these
conditions, relaxation responses to ebselen (n=6), Tempol (n=6) and
PP2 (n=7) were essentially the same as without L-NAME (Supple-
mentary Fig. S1). The eﬀect of Tempol and ebselen on KPSS-induced
contraction was indistinguishable from that of vehicle (Tempol,
7.7± 2.8% block at 3 mM, n=8; ebselen, 10±2% block at 10 µM,
n=8, DMSO, 7.2± 2.1% block, n=6).
We then examined the eﬀect of U46619 on endogenous ROS pro-
duction in PASMC using the Luminol-derived ROS-sensitive chemi-lu-
minescent probe L-012 [27]. U46619 caused a marked increase in su-
peroxide-selective L-012 chemi-luminescence and this increase was
abolished by prior incubation with ebselen or Tempol (Fig. 1D). Basal
chemi-luminescence was all but abolished by Tempol, while ebselen
was without signiﬁcant eﬀect (Fig. 1D). U46619 also enhanced H2O2-
selective chemi-luminescence in IPA as measured using the Promega
ROS-Glo™ H2O2 assay (196±19.4% increase from control, n=3).
3.2. Exogenous ROS cause contraction in a SrcFK-dependent manner
As expected, the membrane permeable quinolinequinone LY83583,
a known generator of intracellular superoxide [15,33,34], increased L-
012 chemi-luminescence, and at 1 µM this increase was similar to that
observed with 100 nM U46619 and was similarly abolished by ebselen
and Tempol (Fig. 2A). While higher doses of LY83583 can directly
constrict IPA [15], 1 µM LY83583 does not itself cause contraction, but
causes a several-fold enhancement of the response to 2 nM U46619,
which is initially ~10% of KPSS in amplitude. When this response was
repeated in the same arteries, but in the presence of ebselen, Tempol or
PP2, with U46619 concentration at 8–10 nM to match pre-constriction
amplitude, the enhancing eﬀect of LY83583 was signiﬁcantly reduced,
while DMSO was without eﬀect (Figs. 2B-2E). To eliminate the possi-
bility that the enhancing eﬀect of LY83583 on U46619-induced con-
traction was as a result of nitric oxide scavenging by superoxide, re-
sponses were repeated in the presence of L-NAME (300 µM, n=6).
Under these conditions, enhancement of the U46619-induced contrac-
tion was essentially the same as without L-NAME (Supplementary Fig.
S1). 30 µM H2O2 also caused contraction in IPA and this contraction
was partially sensitive to inhibition by PP2 (Supplementary Fig. S2A).
To determine the relative contribution of superoxide and H2O2 to
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Fig. 1. Eﬀects of U46619, antioxidants and SrcFK inhibition on contraction and ROS production. A-C: Concentration-dependent relaxation responses to ebselen (A, n=8), Tempol (B,
n=7) and PP2 (C, n=6) in IPA pre-constricted with 100 nM U46619. Left panels: representative traces with arrows indicating where each dose was added. Right panels: mean eﬀects of
inhibitors plotted against DMSO vehicle control (n=5). *P<0.05, **P< 0.01 vs. DMSO control (2-way ANOVA). D: Eﬀect of ebselen (10 µM) or Tempol (3 mM) on U46619-induced
ROS production (15 min, 100 nM, solid bars) or on basal ROS production (open bars) in PASMC, measured by L-012 chemi-luminescence. #P<0.01 vs. control; ##P<0.001 vs. control;
**P< 0.001 vs. U46619 alone (2-way ANOVA, n=10).
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Fig. 2. Eﬀects of exogenous superoxide on U46619-induced contraction in IPA. A: LY83583 (LY, 1 µM, 15 min, n=12) generates superoxide in PASMC, as measured by L-012 chemi-
luminescence), and this is inhibited by ebselen (ebs, 10 µM, n=10) or Tempol (temp, 3 mM, n=10). **P<0.001 vs. control, ##P<0.001 vs. LY alone. B-E: Eﬀects of LY83583 and
inhibitors on U46619-induced contraction in IPA. U46619 concentration was adjusted in each case to produce contractions equivalent to ~10% of KPSS (U46). 1 µM LY83583 was then
added for 10 min (U46+LY). This response was then repeated in the presence of either DMSO vehicle (B, n=6), ebselen (C, 10 µM, n=7), Tempol (D, 3 mM, n=11) or PP2 (E, 30 µM,
n=8). Left panels: representative traces. Right panels: mean± SEM measurements of peak LY83583-induced contraction, expressed as a percentage of the U46619 pre-constriction.
*P< 0.05 vs. U46; **P< 0.01 vs. U46, ##P<0.001 vs. control U46+LY (2-way ANOVA).
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Fig. 3. Eﬀects of U46619, antioxidants and exogenous ROS on c-Src cysteine oxidation, and SrcFK auto-phosphorylation in IPA. A, B: c-Src cysteine oxidation in IPA is signiﬁcantly
enhanced by U46619 (U46, 100 nM, 30 min, n=9), LY83583 (LY, 1 or 10 µM, 30 min, n=7–8) and H2O2 (30 µM, 30 min, n=5). This enhancement and part of the underlying basal
oxidation, is prevented by Tempol (temp, 3 mM, n=6–8). #P<0.05, ##P<0.01 vs. control, **P< 0.01 vs. U46 only or vs. 10-LY only (1-way ANOVA). C: U46619 (100 nM) time-
dependently enhances SrcK auto-phosphorylation (Tyr416) in IPA (n=9, #P<0.05 vs. control, ##P<0.01 vs. control, 1-way ANOVA). D: In the absence of U46, SrcFK auto-
phosphorylation is signiﬁcantly enhanced by LY83583 (1 µM) at 0.5 min (n=16) and 30 min (n=7), #P<0.05 vs. control (1-way ANOVA). E: At 30 min, U46619-induced SrcFK auto-
phosphorylation is inhibited by ebselen (ebs, 10 µM, n=14), Tempol (n=11) or PP2 (30 µM, n=10) #P<0.05 vs. control. F: In the absence of U46, SrcFK auto-phosphorylation is
unaﬀected by ebselen (n=10) or Tempol (n=10) but signiﬁcantly inhibited by PP2 (n=8), ##P<0.001 vs. control, **P<0.001 vs. U46 alone (n=19, 2-way ANOVA).
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Fig. 4. Contribution of ROS and SrcFK to U46619-induced Rho-kinase activity and MLC20 phosphorylation in IPA. U46619 (U46, 100 nM) time-dependently enhances phosphorylation of
MYPT-1 on Thr850 (A), and of MLC20 on Ser19 (B), in IPA (n=8–10, #P<0.05 vs. control, ##P<0.001 vs. control, 1-way ANOVA). C: At 30 min, U46619-induced MYPT-1
phosphorylation is inhibited by ebselen (ebs, 10 µM, n=8), Tempol (temp, 3 mM, n=12) and PP2 (30 µM, n=18) ##P<0.001 vs. control (n=27), **P<0.001 vs. U46 alone, while in
the absence of U46 (D), MYPT-1 phosphorylation was unaﬀected by ebselen (n=11), Tempol (n=12) or PP2 (n=18) (2-way ANOVA). E: Similarly, at 30 min, U46619-induced MLC20
phosphorylation is also inhibited by ebs (n=14), temp (n=12) and PP2 (n=17) ##P<0.001 vs. control (n=27), **P< 0.001 vs. U46 alone, while in the absence of U46 (F), MLC20
phosphorylation is unaﬀected by ebselen (n=13), Tempol (n=12) or PP2 (n=18) (2-way ANOVA).
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U46619-induced contraction, contraction responses to U46619 were
repeated after prior incubation with either catalase alone, to remove
H2O2, or catalase combined with superoxide dismutase (SOD), to re-
move both superoxide and H2O2. As shown in Supplementary Fig. S3 A-
B, catalase alone partially but signiﬁcantly inhibited contraction, while
the combined eﬀect of catalase and SOD caused an even greater degree
of inhibition that was signiﬁcantly greater than catalase alone.
3.3. U46619 and exogenous ROS stimulate c-Src cysteine oxidation, ROS-
dependent SrcFK activity and tyrosine phosphorylation in IPA
Having established that U46619 enhances PASMC ROS production
and that U46619-induced contraction in IPA is dependent on both ROS
and SrcFK, we next investigated whether there was a causative link
between ROS and SrcFK activity. After subjecting IPA lysates to the
PEG-switch protocol [29] for the visualisation of reversible cysteine
oxidation, probing for c-Src revealed additional bands on the Western
blot. The most prominent of these was approximately 5 kDa larger than
the main band (designated c-Src +1-PEG) indicative of oxidation of a
single cysteine residue (Fig. 3A). Although this second band was present
in all samples, its intensity was treatment-speciﬁc, being slightly but
signiﬁcantly enhanced by 100 nM U46619, 1 and 10 µM LY83583 and
30 µM H2O2, and suppressed by Tempol (Fig. 3A, B). Tempol reduced
band intensity signiﬁcantly below control levels, suggesting a degree of
basal c-Src oxidation. A third band, 10–15 kDa above the main c-Src
band was also present in some samples, indicative of multiple cysteine
oxidation (designated c-Src +2/3-PEG), but was too weak for quanti-
ﬁcation. Intensity of the main band (non-oxidised c-Src) was minimally
aﬀected by all treatments applied (Supplementary Fig. S4A). Control
experiments conﬁrm that additional bands indicative of cysteine pe-
gylation are absent when the PEG-maleimide incubation step is omitted
or when the de-salting step alone is performed (Supplementary Fig.
S4B).
U46619 induced biphasic time-dependent increases in SrcFK auto-
phosphorylation (on Tyr416) with peaks at 0.5 min and 30 min
(Fig. 3C). LY83583 and exogenous H2O2 also enhanced SrcFK auto-
phosphorylation in the absence of U46619, suggesting that SrcFK ac-
tivity is ROS sensitive (Fig. 3D, Supplementary Fig. S2B). To corrobo-
rate this, the U46619-induced increase at 30 min was inhibited by prior
incubation with ebselen, Tempol or PP2 (Fig. 3E), while basal SrcFK
phosphorylation was unaﬀected by ebselen, marginally reduced by
Tempol, but only signiﬁcantly inhibited by PP2 (Fig. 3F). To illustrate
the relative contribution of superoxide and H2O2 to U46619-induced
phosphorylation responses, U46619-induced SrcFK auto-phosphoryla-
tion at 30 min was also partially inhibited by catalase and further in-
hibited by the combined action of SOD and catalase, while basal
phosphorylation was unaﬀected by either condition (Supplementary
Fig. S3, C-D).
When blots were probed with anti-phospho-tyrosine to visualise
tyrosine phosphorylation of multiple proteins, it was evident that
LY83583 enhanced this phosphorylation at multiple bands, including
those with approximate MW of 80, 90 and 115 kDa. These three bands
and another band at approximately 140 kDa were sensitive to PP2,
indicative of ROS-induced, SrcFK-dependent phosphorylation
(Supplementary Fig. S5). Taken together, these results suggest a link
between ROS production, SrcFK activation and tyrosine phosphoryla-
tion.
3.4. U46619 stimulates MYPT-1 and MLC20 phosphorylation in IPA in a
ROS-dependent and SrcFK-dependent manner
We reported previously that SrcFK contribute to pulmonary artery
contraction induced by a GPCR agonist (PGF2α) or hypoxia in part by
activating Rho-kinase [11,24] and that superoxide generated by
LY83583 also activates Rho-kinase [15]. To determine whether
U46619-induced activation of Rho-kinase and myosin light-chain
kinase (MLCK) was dependent on both endogenous ROS and SrcFK, we
examined phosphorylation of the Rho-kinase target myosin phospha-
tase targeting subunit-1 (MYPT-1, Thr850) and of myosin light-chain-
20 (MLC20, Ser19), the target of MLCK. U46619 triggered time-de-
pendent increases in phosphorylation of both MYPT-1 (Fig. 4A) and
MLC20 (Fig. 4B). At 30 min, these increases were completely inhibited
by prior incubation with either ebselen, Tempol or PP2 (MYPT-1:
Fig. 4C, MLC20: Fig. 4E), while in the absence of U46619, basal phos-
phorylation of either protein was not signiﬁcantly altered by any of the
three inhibitors (Fig. 4D, F). To illustrate the relative contribution of
superoxide and H2O2 to U46619-induced phosphorylation, both MYPT-
1 and MLC20 phosphorylations induced by U46619 at 30 min were
partially inhibited by catalase and further inhibited by the combined
action of SOD and catalase, while neither condition aﬀected basal
phosphorylation of either protein (Supplementary Fig. S3, E-H).
3.5. Hypoxia-induced SrcFK, MYPT-1 and MLC20 phosphorylation is
dependent on mitochondrial ETC complex I & III
To determine whether hypoxia-induced SrcFK and Rho-kinase ac-
tivity in IPA is dependent on mitochondrial ETC ROS production, we
evaluated the eﬀects of rotenone and myxothiazol, inhibitors of the
source of mitochondrial ROS (complex I and III, respectively) on peak
hypoxia-induced SrcFK (1 min), MYPT-1 (5 min) and MLC20 (5 min)
phosphorylation responses in IPA. Since a small degree of pre-con-
striction is required for a full hypoxic contractile response in IPA [35],
phosphorylation responses were similarly evaluated after priming with
1 nM U46619 for 15 min. Hypoxia enhanced phosphorylation of all
three proteins, and this enhancement was abolished by either rotenone
or myxothiazol (Fig. 5A, C, E). Conversely, the underlying U46619-in-
duced phosphorylation was largely unaﬀected by rotenone or myx-
othiazol and basal phosphorylation totally insensitive to either inhibitor
(Fig. 5B, D, F). U46619-induced contraction (100 nM, 15 min) was not
signiﬁcantly inhibited by pre-incubation with either rotenone (control
46± 14% of KPSS vs. rot 44±15% of KPSS, n=6, paired t-test) or
myxothiazol (control 42± 7% of KPSS vs. myx 30± 4% of KPSS, n=8,
paired t-test).
3.6. U46619 induces ROS-dependent and SrcFK-dependent translocation of
RhoA and ARHGEF-1
Rho-kinase activation requires prior activation of the monomeric G-
protein RhoA, and RhoA activation is often associated with its trans-
location from the cytosol to the plasma membrane [36,37]. We there-
fore visualised and quantiﬁed translocation of EmGFP-tagged RhoA in
live PASMC, as a corollary of RhoA activation, in response to U46619
and LY83583. Under resting conditions, RhoA-EmGFP ﬂuorescence was
localised primarily in the nucleus/perinuclear region, with additional
lower level ﬂuorescence diﬀusely distributed over the rest of the cell. In
the majority of transfected cells examined (> 60%), stimulation with
either U46619 or LY83583 triggered the rapid appearance of highly
localised bright spots or patches on the cell periphery or at prominent
cellular attachment points. RhoA translocation was fully reversible
upon washout. Following an initial response and washout (5 min), cells
were then incubated for 5 min with ebselen, Tempol, PP2 or DMSO
before being re-exposed to either U46619 or LY83583. The second
translocation responses were greatly diminished or abolished by all
three inhibitors, but unaﬀected by DMSO (Fig. 6, Fig. S6). It was also
observed that, upon application of U46619 or LY83583, the reversible
appearance of bright peripheral spots or patches was associated with
concomitant reversible darkening of surrounding cytosolic ﬂuorescence
(Fig. 6, Fig. S9). These changes were conﬁrmed by quantiﬁcation (Fig.
S9), further supporting the assumption that RhoA-EmGFP was indeed
translocating in response to stimulus.
Hypothesising that ROS and SrcFK may be mediating RhoA trans-
location and Rho-kinase activity via interaction with one or more
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Fig. 5. Eﬀects of hypoxia and mitochondrial ETC inhibitors on SrcFK, MYPT-1 and MLC20 phosphorylation in IPA. A: Hypoxia (1% O2, 1 min) enhances SrcFK auto-phosphorylation
following priming with U46619 (U46, 1 nM, 15 min), and this enhancement is prevented by myxothiazol (myx, 100 nM) or rotenone (rot, 100 nM). #P<0.05 vs. U46 alone, *P< 0.05
vs. U46/1% O2 (2-way ANOVA, n=9–10). B: Myxothiazol alone or rotenone alone has no signiﬁcant eﬀect on SrcFK auto-phosphorylation (1-way ANOVA, n=8–9). C: Hypoxia (1% O2,
5 min) enhances MYPT-1 phosphorylation following priming with U46619 (U46, 1 nM, 15 min), and this enhancement is prevented by myxothiazol (myx, 100 nM) or rotenone (rot,
100 nM). ##P<0.01 vs. U46 alone, **P< 0.01 vs. U46/1% O2 (2-way ANOVA, n=9–10). D: Myxothiazol or rotenone alone (in the absence of contractile stimuli) have no signiﬁcant
eﬀect on MYPT-1 phosphorylation (1-way ANOVA, n=9–11). E: Hypoxia (1% O2, 5 min) enhances MLC20 phosphorylation following priming with U46619 (U46, 1 nM, 15 min), and this
enhancement is prevented by myxothiazol (myx, 100 nM) or rotenone (rot, 100 nM) #P<0.05 vs. U46 alone, *P< 0.05 vs. U46/1% O2 (2-way ANOVA, n=9–10). F: Myxothiazol or
rotenone alone (in the absence of contractile stimuli) have no signiﬁcant eﬀect on MLC20 phosphorylation (1-way ANOVA, n=9–10).
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Fig. 6. Eﬀects of U46619, LY83583, antioxidants and SrcFK inhibition on RhoA-EmGFP translocation in PASMC. A-D: Fluorescent imaging of representative RhoA-EmGFP transfected
PASMC at rest (left panels), in the presence of stimulus (middle panels A-B: U46619, U46, 100 nM or C-D: LY83583, LY, 1 µM) or after washout followed by repeated exposure to stimulus
in the presence of either Tempol, PP2 or ebselen (right panels). E-F: Quantiﬁcation of spot/patch ﬂuorescence intensity expressed as % change above control levels during sti-
mulus± inhibition (E: U46619, F: LY83583). ##P<0.001 vs. baseline, **P< 0.001 vs. U46619, 2-way ANOVA, n=8–11 cells from a total of seven diﬀerent cell lines. Each mea-
surement is combined from at least 3 spots/patches from each cell. See supplementary Fig. S6 for control responses.
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Fig. 7. ARGHEF1-EmGFP translocates in response to U46619 and LY83583 in PASMC and co-localises with c-Src in IPA. A-C: Fluorescent imaging of representative ARHGEF1-EmGFP
transfected PASMC at rest (left panels), in the presence of stimulus (middle panels A-B: U46619, U46, 100 nM or C: LY83583, LY, 1 µM) or after washout followed by repeated exposure to
stimulus in the presence of either Tempol or PP2 (right panels). D-E: Quantiﬁcation of spot/patch ﬂuorescence intensity expressed as % change above control levels during sti-
mulus± inhibition (D: U46619, E: LY83583). ##P<0.001 vs. baseline, **P< 0.001 vs. U46619, 2-way ANOVA, n=8–9 cells from a total of seven diﬀerent cell lines. Each mea-
surement is combined from at least 3 spots/patches from each cell. See supplementary Fig. S8 for control responses. F: Co-localisation of ARHGEF1 with c-Src in IPA. Representative blots
show the eﬀect of U46619 (100 nM, 30 min) on ARHGEF1 content (WB: GEF1) and c-Src content (WB: c-Src) after c-Src immuno-precipitation (IP: c-Src), with GAPDH content in the un-
bound fraction as a loading control (WB: GAPDH). Bar charts show that U46619 treatment increases ARHGEF1 co-immuno-precipitation with c-Src and that this is prevented by pre-
incubation with Tempol (3 mM). ARHGEF1 content expressed relative to both c-Src IP content and GAPDH loading control. c-Src IP content is unaﬀected by treatment. ##P<0.0.1 vs.
control, *P< 0.05, **P< 0.01 vs. U46, 1-way ANOVA, n=6.
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RhoGEFs, we also examined the involvement of ARHGEF1, a RhoA-
speciﬁc guanine nucleotide exchange factor. Expression of native
ARHGEF1 in IPA was conﬁrmed by PCR (Fig. S7). In parallel with
RhoA-EmGFP translocation, we also examined the translocation re-
sponses of EmGFP-tagged ARHGEF1 in live PASMC, in response to
U46619 and LY83583. ARHGEF1-EmGFP responded to both stimuli
with a pattern of translocation similar to that of RhoA-EmGFP, being
similarly stimulated by U46619 or LY83583 and similarly inhibited by
Tempol, ebselen or PP2 (Fig. 7A-E, Figs. S8 & S9), although it was no-
ticeably absent from nuclei and less persistent than for RhoA, fading
after several seconds. To further clarify the relationship between SrcFK
and ARHGEF1, we also examined their physical association in IPA and
its ROS-dependence by co-immunoprecipitation. As shown in Fig. 7F,
ARHGEF1 was co-immunoprecipitated with c-Src and this co-im-
munoprecipitation was enhanced by U46619 and prevented by the
antioxidant Tempol.
3.7. RhoA translocation and contraction induced by U46619 and LY83583
require RhoGEF activity
If ARHGEF1 translocates and associates with c-Src in response to
contractile stimuli, it is possible that activation of RhoA and contraction
are also dependent on ARHGEF1. We ﬁrst tested this hypothesis by
examining translocation of RhoA-EmGFP in PASMC co-transfected with
an siRNA against ARHGEF1. Secondly, we determined the eﬀects of Y16
on U46619 and LY83583-induced contraction. Y16 is an inhibitor of the
RGS domain-containing sub-family of RhoA-speciﬁc RhoGEFs, which
includes ARHGEF1 [38]. In PASMC co-transfected with a control
(scrambled) siRNA, both U46619 and LY83583 triggered translocation
of RhoA-EmGFP in a manner similar to that described in Fig. 6. In
contrast, this translocation was nearly absent in PASMC co-transfected
with ARHGEF1 siRNA (Fig. 8A-D). In IPA pre-constricted with 100 nM
U46619, Y16 caused concentration-dependent relaxation (Fig. 8E) and
in IPA contracted by 1 µM LY83583 following pre-constricted with low-
dose U46619 (< 20 nM), the LY83583-induced enhancement was sig-
niﬁcantly inhibited by 10 µM Y16 (Fig. 8F). Thus, ROS-dependent
contraction of IPA requires the activation of a RhoGEF, probably
ARHGEF1, upstream of RhoA/Rho-kinase.
4. Discussion
It is generally accepted that ROS are important signalling molecules
in vascular function. However, their involvement in normal vascular
smooth muscle contractile responses in general, and Rho-kinase acti-
vation in particular, remains to be fully characterised. We hypothesised
that SrcFK act as proximal ROS-activated molecular switches in rat IPA,
responding to endogenous and exogenous ROS signals in order to ac-
tivate Rho-kinase and contribute to contraction. We also sought to link
SrcFK to Rho-kinase via RhoGEF and RhoA activation in this model.
Here we showed that U46619, an agonist for the G-protein coupled T-
type prostanoid receptor, enhances ROS production in PASMC, and as
expected, antioxidants fully inhibited U46619-induced ROS production.
Although we haven’t determined the source of ROS in this study, it is
most likely derived from NADPH oxidase, as has been previously de-
scribed for U46619 and other agonists in this tissue [1,39], as well as
for multiple other G-protein coupled receptor agonists in various other
vascular preparations [40–42].
4.1. Sequential activation of SrcFK and Rho-kinase by endogenous and
exogenous ROS
SrcFK auto-phosphorylation is a recognised indicator of SrcFK ac-
tivity [43], while the phosphorylation of MYPT-1 on Thr850 by Rho-
kinase results in disassembly of myosin light-chain phosphatase [44].
We showed that the two structurally unrelated non-selective anti-
oxidants ebselen and Tempol [31,32] inhibit U46619-induced
contraction, SrcFK auto-phosphorylation (Tyr416) and phosphorylation
of MYPT-1 (Thr850) and MLC20 (Ser19). These experiments conﬁrm the
importance of endogenous ROS in U46619-induced SrcFK activity, Rho-
kinase activity and contraction in IPA. Neither antioxidant nor com-
bined SOD/catalase had any eﬀect on basal phosphorylation of SrcFK,
MYPT-1 or MLC20, suggesting that only agonist-induced ROS, not basal
ROS, contributes to the activation of SrcFK and Rho-kinase. U46619-
induced contraction and all three phosphorylation responses were also
inhibited by the selective SrcFK antagonist PP2 [45], thus conﬁrming
previous reports that SrcFK are acting upstream of Rho-kinase in this
model [24].
The fact that individually, Tempol, ebselen and PP2 all completely
prevent U46619-induced phosphorylation responses suggests that ROS
and SrcFK may be acting as part of the same signalling pathway, re-
sulting in activation of Rho-kinase and MLCK. To test this assumption
and to examine the relative contribution of superoxide and H2O2 to this
signalling pathway, we also examined the eﬀects of exogenous ROS on
contraction and phosphorylation responses. LY83583 is a quinoline-
quinone that acts as a substrate for the enzyme quinone oxidoreductase,
thus enhancing cytosolic superoxide generation [33]. We previously
showed that low dose LY83583 greatly enhances PGF2α-induced Rho-
kinase activity and contraction in IPA [15]. In the present study, we
demonstrated a similar enhancement of a U46619-induced pre-con-
striction by LY83583 and that this enhancement was dependent on both
ROS (Tempol- and ebselen-sensitive) and SrcFK (PP2-sensitive). Fur-
thermore, LY83583 induced PP2-sensitive SrcFK auto-phosphorylation
and tyrosine phosphorylation of multiple proteins in IPA. We also
showed that exogenously applied H2O2 induced PP2-sensitive contrac-
tion and SrcFK auto-phosphorylation in IPA. Therefore, both superoxide
and H2O2 are capable of activating SrcFK. We previously showed that
while 30 µM H2O2 raises intracellular [Ca2+] in PASMC, it does not
inﬂuence MYPT-1 phosphorylation [16] and does not induce Rho-ki-
nase translocation, while LY83583 does both [15]. Furthermore, the
LY83583-induced translocation was prevented by SOD, suggesting that
ROS-induced activation of Rho-kinase in IPA is superoxide-speciﬁc.
However, in the present study, we found that contraction and phos-
phorylation responses to U46619 were partially inhibited by catalase
and further inhibited by combined SOD/catalase, suggesting both su-
peroxide and H2O2 contribute to this kinase activity and contraction in
response to GPCR stimulation. One potential implication of this result is
that endogenously (intracellular) generated H2O2 has diﬀerent actions to
that applied exogenously. This may be related to the normal compart-
mentalisation of cellular ROS generators, ROS eﬀectors and cellular
antioxidant systems being disrupted by the application of exogenous
H2O2 [6,46].
Having established that U46619-induced SrcFK activity is ROS-de-
pendent, we sought to determine whether this occurred via direct oxi-
dation of c-Src. Our cysteine oxidation data suggest that at least a
component of the ROS-dependent activation of c-Src occurs via this
route. The appearance of additional c-Src bands following pegylation of
oxidised cysteine residues, particularly one approximately 5 kDa larger
than the main band, suggests oxidation of a single cysteine residue on c-
Src [29]. Intensiﬁcation of this band by U46619, LY83583 and H2O2
and prevention of this intensiﬁcation by Tempol, suggest that both
exogenous and endogenous ROS are oxidising a fraction of cellular c-Src
in IPA. Intensity of the main non-pegylated c-Src band was not sig-
niﬁcantly reduced by any of the treatments, suggesting that most of the
cellular c-Src remains in the non-oxidised state. It may be that the re-
latively small fraction of total cellular c-Src that is being oxidised under
these conditions fully accounts for the subsequently observed ROS-de-
pendent downstream signalling events, since broadly similar order of
magnitude increases in c-Src oxidation and SrcFK auto-phosphorylation
were recorded in response to U46619 and LY83583. There is previous
evidence in other tissues for activation of c-Src by direct cysteine oxi-
dation, particularly Cys487 and Cys235, which when oxidised, trigger
auto-phosphorylation [47]. Alternatively, there may also be indirect
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activation of SrcFK through oxidative inhibition of negative regulators
of SrcFK, such as c-Src kinase or speciﬁc tyrosine phosphatases [48,49].
Taken together, the results so far suggest a sequence of events starting
with ROS production, followed by ROS-dependent activation of SrcFK,
and subsequent activation of Rho-kinase and contraction.
SrcFK and Rho-kinase are also both activated by hypoxia in
(caption on next page)
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pulmonary artery and are major contributors to hypoxic pulmonary
vasoconstriction (HPV), and as with G-protein coupled receptor sig-
nalling, we have shown that SrcFK is acting upstream of Rho-kinase in
response to hypoxia [11]. However, in that previous study we did not
establish the role of endogenous ROS in Rho-kinase activation. There is
strong evidence that HPV is initiated by increased generation of ROS
from complex III of the mitochondrial ETC, and HPV has been shown to
be abolished by inhibitors of complex I and III such as rotenone and
myxothiazol, as well as by antioxidants, including ebselen and Tempol
[9,50,51], also reviewed in [10]. The data reported here complements
such reports by showing that myxothiazol and rotenone inhibited hy-
poxia-induced SrcFK auto-phosphorylation and, as predicted by the
ROS-sensitivity of Rho-kinase, they also inhibited MYPT-1 and MLC20
phosphorylation induced by hypoxia. The relative selectivity of rote-
none and myxothiazol for mitochondrial over GPCR-induced ROS are
conﬁrmed by the lack of signiﬁcant eﬀect of these inhibitors on
U46619-induced SrcFK/MYPT1/MLC20 phosphorylation. Together
these results are consistent with the concept that SrcFK are activated by
mitochondrial ROS and mediate the subsequent activation of Rho-ki-
nase during HPV. Notably, as rotenone and myxothiazol block HPV [9],
but did not signiﬁcantly aﬀect U46619-induced contraction (this
study), mitochondria are unlikely to be the source of the U46619-in-
duced elevation of ROS, which as discussed above, is more probably
NADPH oxidase [1,2,9].
4.2. Interaction between ROS, SrcFK, AHRGEF1 and RhoA
Having established that SrcFK contribute to ROS-mediated Rho-ki-
nase activation in response to U46619 stimulation and hypoxia, we
attempted to further clarify the link between SrcFK and Rho-kinase by
identifying molecular targets/binding partners for SrcFK. Rho-kinase
requires prior activation of the monomeric G-protein RhoA [52], and
while neither RhoA nor Rho-kinase are known to require direct tyrosine
phosphorylation, several members of the Rho guanine nucleotide ex-
change factor (RhoGEF) family of proteins which activate RhoA by
promoting the exchange of bound GDP for bound GTP, have been
shown to be activated by direct tyrosine phosphorylation [26,53–55],
in addition to or instead of interaction with Gα12/13 [19,56]. These in-
clude the RGS domain-containing GEFs ARHGEF1 (p115-RhoGEF),
ARHGEF11 (PDZ-RhoGEF) and ARHGEF12 (LARG), amongst others.
Inhibition of U46619 or LY83583 induced contraction by Y16, a se-
lective inhibitor of RhoA activation by RGS-domain containing Rho-
GEFs [38], supports the importance of these proteins.
We speciﬁcally chose to examine ARHGEF1 in more detail because
it has previously been implicated in AngII-induced hypertension and
shown to be tyrosine phosphorylated by Janus kinase-2 (JAK2) in
mesenteric artery as an essential step in its activation by AngII [26]. In
live PASMC we examined translocation of EmGFP-tagged RhoA and
EmGFP-tagged ARHGEF1, during stimulation by U46619 or LY83583.
We found that both stimuli triggered reversible and reproducible
translocation of both proteins to distinct spots or patches on the cellular
periphery, and that these responses were dependent on both SrcFK
activity (PP2-inhibitable) and ROS (Tempol or ebselen-inhibitable).
Although further work would be required to identify the cellular
structures to which the two proteins translocate, previous studies sug-
gest they may be integrin-associated focal attachments [57,58].
Assuming that this translocation does indeed precede or is concomitant
with ARHGEF1 and RhoA activation [36,56], our results suggest that
ROS and SrcFK are likely to be stimulating Rho-kinase via prior acti-
vation of ARHGEF1, followed by activation of RhoA. Direct activation
of RhoA by ROS independently of RhoGEF binding has been described
previously [18], but this is unlikely to be contributing to our results
because RhoA translocation induced by either U46619 or LY83583 was
nearly abolished by co-transfection with an ARHGEF1 siRNA, con-
ﬁrming that ROS-dependent and SrcFK-dependent activation of
ARHGEF1 is likely to be an essential step in the activation of RhoA and
therefore of Rho-kinase. While U46619 will be inducing translocation
via a G-protein coupled receptor, subsequent NOX-derived ROS pro-
duction and SrcFK activity, LY83583 will be doing so via ROS and
SrcFK, but independently of a G-protein coupled receptor. Thus, al-
though ARHGEF1 is previously known to require direct activated by
G12/13 [19,56], our results suggest that ARHGEF1 may be activatable by
any stimuli that induce ROS production and or SrcFK-dependent tyr-
osine kinase activity.
Our observation that co-immunoprecipitation of ARHGEF1 and c-
Src in IPA is enhanced by U46619 suggests that a close association
between the two proteins may occur. Furthermore, the co-im-
munoprecipitation was prevented by Tempol, suggesting that the as-
sociation is ROS-dependent. This is also supported by the observation
that LY83583 (this study) and PGF2α [24] both enhance SrcFK-depen-
dent tyrosine phosphorylation of multiple proteins in IPA, including
one at approximately 115 kDa, the expected location of ARHGEF1. The
co-immunoprecipitation of c-Src and ARHGEF1 was recorded after
10 min exposure to U46619, so the complex thus formed is presumably
quite stable. Further studies would be required to determine whether
this indicates direct phosphorylation of ARHGEF1 by c-Src. Although
there is a precedent for the requirement of such phosphorylation in
ARHGEF1 activation, albeit by JAK2 [26], there is as yet no direct
evidence that members of the Src family of kinases themselves phos-
phorylate any RhoGEF other than the oncogenic Vav or Tiam1, despite
being implicated in activation of both RhoA and Rac-1 [59,60]. SrcFK
are, however, known to phosphorylate and activate other non-receptor
tyrosine kinases such as focal adhesion kinase, PYK2 and JAK2, in re-
sponse to multiple stimuli, including G-protein coupled receptors and
exogenous ROS [61–65], while all three of the aforementioned kinases
have been shown to phosphorylate RhoGEFs [26,66,67]. It is reason-
able to suggest, therefore, that if not directly, SrcFK may be mediating
the activation of ARHGEF1 and RhoA via one or more of these other
kinases.
5. Conclusion
Our study characterises a contractile signalling pathway in pul-
monary artery that incorporates ROS, SrcFK, ARHGEF1, RhoA and Rho-
kinase. As outlined in the graphical summary (Fig. 9), we identify SrcFK
as key proximal ROS eﬀectors in response to both GPCR activation and
hypoxia. We also propose ARHGEF1 as a possible target for ROS-de-
pendent SrcFK activity upstream of RhoA/Rho-kinase activation in IPA
contractile responses. Further investigation into the interaction be-
tween these proteins downstream of ROS production, particularly
SrcFK, ARHGEF1 and Rho-kinase, may inform the identiﬁcation of new
therapeutic targets for the treatment of cardiovascular diseases
Fig. 8. Eﬀects of RhoGEF inhibition on U46619 and ROS-induced RhoA translocation and contraction. A-D: Fluorescence imaging of RhoA-EmGFP translocation in PASMC, co-transfected
with ARHGEF1 siRNA or scrambled siRNA, stimulated with U46619 (A: U46, 100 nM) or LY83583 (C: LY, 1 µM). Quantiﬁcation of spot/patch ﬂuorescence intensity expressed as %
change above control levels during stimulus± inhibition (B: U46619, D: LY83583). ##P<0.001 vs. baseline, **P< 0.001 vs. treatment, 2-way ANOVA, n=12–16 cells from a total of
three diﬀerent cell lines. Each measurement is combined from at least 3 spots/patches from each cell. E: Concentration-dependent relaxation responses Y16 (10 µM) in IPA pre-constricted
with 100 nM U46619. Left panels: representative traces with arrows indicating where each dose was added. Right panels: mean eﬀects of inhibitor plotted against DMSO vehicle control
(n=12). *P< 0.05, **P<0.01 vs. DMSO control (2-way ANOVA). F: Eﬀects of LY83583 and Y16 on U46619-induced contraction in IPA. U46619 concentration was adjusted in each
case to produce contractions equivalent to ~10% of KPSS. 1 µM LY83583 was then added for 10 min (U46+LY). This response was then repeated in the presence of Y16 (10 µM, n=13).
Left panels: representative traces. Right panels: mean± SEM measurements of peak LY83583-induced contraction, expressed as a percentage of the U46619 pre-constriction. **P< 0.01
vs. U46, ##P<0.001 vs. control U46+LY (2-way ANOVA).
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associated with oxidative stress, such as pulmonary hypertension.
Funding
This work was supported by British Heart Foundation [grant
number FS/12/43/29608 to G.K.] and Wellcome Trust [grant #087776
to J.P.W].
Conﬂict of interest
None.
Acknowledgments
The authors wish to thank Prof Philip Eaton and Dr Joseph
Burgoyne for advice on application of the PEG-switch assay to this
study.
Appendix A. Supplementary material
Supplementary data associated with this article can be found in the
online version at http://dx.doi.org/10.1016/j.freeradbiomed.2017.06.
022.
References
[1] Y. Shaifta, V.A. Snetkov, J. Prieto-Lloret, G.A. Knock, S.V. Smirnov, P.I. Aaronson,
et al., Sphingosylphosphorylcholine potentiates vasoreactivity and voltage-gated
Ca2+ entry via NOX1 and reactive oxygen species, Cardiovasc. Res. 106 (2015)
121–130.
[2] G.B. Waypa, J.D. Marks, R.D. Guzy, P.T. Mungai, J.M. Schriewer, D. Dokic, et al.,
Superoxide generated at mitochondrial complex III triggers acute responses to hy-
poxia in the pulmonary circulation, Am. J. Respir. Crit. Care Med. 187 (2013)
424–432.
[3] D.E. Fomenko, W. Xing, B.M. Adair, D.J. Thomas, V.N. Gladyshev, High-throughput
identiﬁcation of catalytic redox-active cysteine residues, Science 315 (2007)
387–389.
[4] G.A. Knock, J.P. Ward, Redox regulation of protein kinases as a modulator of
vascular function, Antioxid. Redox Signal. 15 (2011) 1531–1547.
[5] H. Miki, Y. Funato, Regulation of intracellular signalling through cysteine oxidation
by reactive oxygen species, J. Biochem. 151 (2012) 255–261.
[6] Y.M. Janssen-Heininger, B.T. Mossman, N.H. Heintz, H.J. Forman,
B. Kalyanaraman, T. Finkel, et al., Redox-based regulation of signal transduction:
principles, pitfalls, and promises, Free Radic. Biol. Med. 45 (2008) 1–17.
[7] M. Santillo, A. Colantuoni, P. Mondola, B. Guida, S. Damiano, NOX signaling in
molecular cardiovascular mechanisms involved in the blood pressure homeostasis,
Front. Physiol. 6 (2015) 194.
[8] K.K. Griendling, D. Sorescu, B. Lassegue, M. Ushio-Fukai, Modulation of protein
kinase activity and gene expression by reactive oxygen species and their role in
vascular physiology and pathophysiology, Arterioscler. Thromb. Vasc. Biol. 20
(2000) 2175–2183.
[9] R.M. Leach, H.M. Hill, V.A. Snetkov, T.P. Robertson, J.P. Ward, Divergent roles of
glycolysis and the mitochondrial electron transport chain in hypoxic pulmonary
vasoconstriction of the rat: identity of the hypoxic sensor, J. Physiol. 536 (2001)
211–224.
[10] J.T. Sylvester, L.A. Shimoda, P.I. Aaronson, J.P. Ward, Hypoxic pulmonary vaso-
constriction, Physiol. Rev. 92 (2012) 367–520.
[11] G.A. Knock, V.A. Snetkov, Y. Shaifta, S. Drndarski, J.P. Ward, P.I. Aaronson, Role of
src-family kinases in hypoxic vasoconstriction of rat pulmonary artery, Cardiovasc.
Res. 80 (2008) 453–462.
[12] T.P. Robertson, M. Dipp, J.P. Ward, P.I. Aaronson, A.M. Evans, Inhibition of sus-
tained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and
perfused lung of the rat, Br. J. Pharmacol. 131 (2000) 5–9.
[13] V.A. Snetkov, G.A. Knock, L. Baxter, G.D. Thomas, J.P. Ward, P.I. Aaronson,
Mechanisms of the prostaglandin F2alpha-induced rise in [Ca2+]i in rat in-
trapulmonary arteries, J. Physiol. 571 (2006) 147–163.
[14] A.P. Somlyo, A.V. Somlyo, Ca2+ sensitivity of smooth muscle and nonmuscle
myosin II: modulated by G proteins, kinases, and myosin phosphatase, Physiol. Rev.
83 (2003) 1325–1358.
[15] G.A. Knock, V.A. Snetkov, Y. Shaifta, M. Connolly, S. Drndarski, A. Noah, et al.,
Fig. 9. Graphical Summary. ROS-induced contractile signalling pathway in rat pulmonary artery. Reactive oxygen species (ROS: superoxide and H2O2) generated in response to
GPCR (presumably via NADPH-oxidase, NOX), LY83583 (via quinone oxidoreductase, QOR), or hypoxia (from mitochondria, mito), activate Src-family kinases (SrcFK) either via direct
oxidation or via oxidative inhibition of c-Src kinase (CSK) or inhibitory tyrosine phosphatases (PTP). This is followed by sequential activation of ARHGEF1, RhoA and Rho-kinase,
resulting in enhanced MYPT-1 and MLC20 phosphorylation and contraction. Boxed red text indicates treatments/antagonists that inhibit responses or activity of each component in the
pathway. Temp/ebs = antioxidants Tempol & ebselen; SOD/cat = superoxide dismutase and catalase; PP2 = SrcFK inhibitor; rot/myx =mitochondrial electron transfer chain inhibitors
rotenone &myxothiazol; Y16 = inhibitor of RGS domain containing RhoAGEFs. Question mark indicates steps shown previously but not examined in this study.
C.E. MacKay et al. Free Radical Biology and Medicine 110 (2017) 316–331
330
Superoxide constricts rat pulmonary arteries via Rho-kinase-mediated Ca(2+)
sensitization, Free Radic. Biol. Med. 46 (2009) 633–642.
[16] G.E. Pourmahram, V.A. Snetkov, Y. Shaifta, S. Drndarski, G.A. Knock, P.I. Aaronson,
et al., Constriction of pulmonary artery by peroxide: role of Ca2+ release and PKC,
Free Radic. Biol. Med. 45 (2008) 1468–1476.
[17] M. Jaiswal, L. Gremer, R. Dvorsky, L.C. Haeusler, I.C. Cirstea, K. Uhlenbrock, et al.,
Mechanistic insights into speciﬁcity, activity, and regulatory elements of the reg-
ulator of G-protein signaling (RGS)-containing Rho-speciﬁc guanine nucleotide
exchange factors (GEFs) p115, PDZ-RhoGEF (PRG), and leukemia-associated
RhoGEF (LARG), J. Biol. Chem. 286 (2011) 18202–18212.
[18] A. Aghajanian, E.S. Wittchen, S.L. Campbell, K. Burridge, Direct activation of RhoA
by reactive oxygen species requires a redox-sensitive motif, PLoS One 4 (2009)
e8045.
[19] Z. Chen, L. Guo, J. Hadas, S. Gutowski, S.R. Sprang, P.C. Sternweis, Activation of
p115-RhoGEF requires direct association of Galpha13 and the Dbl homology do-
main, J. Biol. Chem. 287 (2012) 25490–25500.
[20] S. Siehler, Regulation of RhoGEF proteins by G12/13-coupled receptors, Br. J.
Pharmacol. 158 (2009) 41–49.
[21] I.F. McMurtry, K. Abe, H. Ota, K.A. Fagan, M. Oka, Rho kinase-mediated vaso-
constriction in pulmonary hypertension, Adv. Exp. Med. Biol. 661 (2010) 299–308.
[22] S.S. Pullamsetti, E.M. Berghausen, S. Dabral, A. Tretyn, E. Butrous, R. Savai, et al.,
Role of Src tyrosine kinases in experimental pulmonary hypertension, Arterioscler.
Thromb. Vasc. Biol. 32 (2012) 1354–1365.
[23] S. Saito, G.D. Frank, M. Mifune, M. Ohba, H. Utsunomiya, E.D. Motley, et al.,
Ligand-independent trans-activation of the platelet-derived growth factor receptor
by reactive oxygen species requires protein kinase C-delta and c-Src, J. Biol. Chem.
277 (2002) 44695–44700.
[24] G.A. Knock, Y. Shaifta, V.A. Snetkov, B. Vowles, S. Drndarski, J.P. Ward, et al.,
Interaction between src family kinases and rho-kinase in agonist-induced Ca2+-
sensitization of rat pulmonary artery, Cardiovasc. Res. 77 (2008) 570–579.
[25] G. Sun, D.J. Kemble, To C or not to C: direct and indirect redox regulation of Src
protein tyrosine kinase, Cell Cycle 8 (2009) 2353–2355.
[26] C. Guilluy, J. Bregeon, G. Toumaniantz, M. Rolli-Derkinderen, K. Retailleau,
L. Loufrani, et al., The Rho exchange factor Arhgef1 mediates the eﬀects of an-
giotensin II on vascular tone and blood pressure, Nat. Med. 16 (2010) 183–190.
[27] A. Daiber, M. August, S. Baldus, M. Wendt, M. Oelze, K. Sydow, et al., Measurement
of NAD(P)H oxidase-derived superoxide with the luminol analogue L-012, Free
Radic. Biol. Med. 36 (2004) 101–111.
[28] X. Lu, F. Wang, M. Liu, K.T. Yang, A. Nau, D.E. Kohan, et al., Activation of ENaC in
collecting duct cells by prorenin and its receptor PRR: involvement of Nox4-derived
hydrogen peroxide, Am. J. Physiol. Ren. Physiol. 310 (2016) F1243–F1250.
[29] J.R. Burgoyne, O. Oviosu, P. Eaton, The PEG-switch assay: a fast semi-quantitative
method to determine protein reversible cysteine oxidation, J. Pharmacol. Toxicol.
Methods 68 (2013) 297–301.
[30] Y. Shaifta, N. Irechukwu, J. Prieto-Lloret, C.E. MacKay, K.A. Marchon, J.P. Ward,
et al., Divergent modulation of Rho-kinase and Ca(2+) inﬂux pathways by Src
family kinases and focal adhesion kinase in airway smooth muscle, Br. J.
Pharmacol. 172 (2015) 5265–5280.
[31] Z. Luo, Y. Chen, S. Chen, W.J. Welch, B.T. Andresen, P.A. Jose, et al., Comparison of
inhibitors of superoxide generation in vascular smooth muscle cells, Br. J.
Pharmacol. 157 (2009) 935–943.
[32] C.S. Wilcox, A. Pearlman, Chemistry and antihypertensive eﬀects of tempol and
other nitroxides, Pharmacol. Rev. 60 (2008) 418–469.
[33] T. Hasegawa, A. Bando, K. Tsuchiya, S. Abe, M. Okamoto, K. Kirima, et al.,
Enzymatic and nonenzymatic formation of reactive oxygen species from 6-anilino-
5,8-quinolinequinone, Biochim. Biophys. Acta 1670 (2004) 19–27.
[34] V.A. Snetkov, S.V. Smirnov, J. Kua, P.I. Aaronson, J.P. Ward, G.A. Knock,
Superoxide diﬀerentially controls pulmonary and systemic vascular tone through
multiple signalling pathways, Cardiovasc. Res. 89 (2011) 214–224.
[35] R.M. Leach, T.P. Robertson, C.H. Twort, J.P. Ward, Hypoxic vasoconstriction in rat
pulmonary and mesenteric arteries, Am. J. Physiol. 266 (1994) L223–L231.
[36] M. Mori, H. Tsushima, Vanadate activates Rho A translocation in association with
contracting eﬀects in ileal longitudinal smooth muscle of guinea pig, J. Pharmacol.
Sci. 95 (2004) 443–451.
[37] Z. Ying, F.R. Giachini, R.C. Tostes, R.C. Webb, Salicylates dilate blood vessels
through inhibiting PYK2-mediated RhoA/Rho-kinase activation, Cardiovasc. Res.
83 (2009) 155–162.
[38] X. Shang, F. Marchioni, C.R. Evelyn, N. Sipes, X. Zhou, W. Seibel, et al., Small-
molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange
factors, Proc. Natl. Acad. Sci. USA 110 (2013) 3155–3160.
[39] S. Chakraborti, S. Roy, A. Mandal, K. Dey, A. Chowdhury, S. Shaikh, et al., Role of
PKCalpha-p(38)MAPK-G(i)alpha axis in NADPH oxidase derived O(2)(.-)-mediated
activation of cPLA(2) under U46619 stimulation in pulmonary artery smooth
muscle cells, Arch. Biochem. Biophys. 523 (2012) 169–180.
[40] A.K. Banes-Berceli, S. Ogobi, A. Tawﬁk, B. Patel, A. Shirley, D.M. Pollock, et al.,
Endothelin-1 activation of JAK2 in vascular smooth muscle cells involves NAD(P)H
oxidase-derived reactive oxygen species, Vascul. Pharmacol. 43 (2005) 310–319.
[41] M.S. El-Awady, H.R. Ansari, D. Fil, S.L. Tilley, S.J. Mustafa, NADPH oxidase
pathway is involved in aortic contraction induced by A3 adenosine receptor in
mice, J. Pharmacol. Exp. Ther. 338 (2011) 711–717.
[42] N.R. Madamanchi, S.K. Moon, Z.S. Hakim, S. Clark, A. Mehrizi, C. Patterson, et al.,
Diﬀerential activation of mitogenic signaling pathways in aortic smooth muscle
cells deﬁcient in superoxide dismutase isoforms, Arterioscler. Thromb. Vasc. Biol.
25 (2005) 950–956.
[43] W. Xu, A. Doshi, M. Lei, M.J. Eck, S.C. Harrison, Crystal structures of c-Src reveal
features of its autoinhibitory mechanism, Mol. Cell 3 (1999) 629–638.
[44] G. Velasco, C. Armstrong, N. Morrice, S. Frame, P. Cohen, Phosphorylation of the
regulatory subunit of smooth muscle protein phosphatase 1M at Thr850 induces its
dissociation from myosin, FEBS Lett. 527 (2002) 101–104.
[45] X. Zhu, J.L. Kim, J.R. Newcomb, P.E. Rose, D.R. Stover, L.M. Toledo, et al.,
Structural analysis of the lymphocyte-speciﬁc kinase Lck in complex with non-se-
lective and Src family selective kinase inhibitors, Structure 7 (1999) 651–661.
[46] J.P. Ward, Physiological redox signalling and regulation of ion channels: implica-
tions for pulmonary hypertension, Exp. Physiol. (2016).
[47] E. Giannoni, F. Buricchi, G. Raugei, G. Ramponi, P. Chiarugi, Intracellular reactive
oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-
dependent cell growth, Mol. Cell Biol. 25 (2005) 6391–6403.
[48] J.E. Mills, P.C. Whitford, J. Shaﬀer, J.N. Onuchic, J.A. Adams, P.A. Jennings, A
novel disulﬁde bond in the SH2 Domain of the C-terminal Src kinase controls cat-
alytic activity, J. Mol. Biol. 365 (2007) 1460–1468.
[49] R. Roskoski Jr., Src kinase regulation by phosphorylation and dephosphorylation,
Biochem. Biophys. Res. Commun. 331 (2005) 1–14.
[50] M.J. Connolly, J. Prieto-Lloret, S. Becker, J.P. Ward, P.I. Aaronson, Hypoxic pul-
monary vasoconstriction in the absence of pretone: essential role for intracellular
Ca2+ release, J. Physiol. 591 (2013) 4473–4498.
[51] G.B. Waypa, J.D. Marks, M.M. Mack, C. Boriboun, P.T. Mungai, P.T. Schumacker,
Mitochondrial reactive oxygen species trigger calcium increases during hypoxia in
pulmonary arterial myocytes, Circ Res. 91 (2002) 719–726.
[52] T. Matsui, M. Amano, T. Yamamoto, K. Chihara, M. Nakafuku, M. Ito, et al., Rho-
associated kinase, a novel serine/threonine kinase, as a putative target for small
GTP binding protein Rho, EMBO J. 15 (1996) 2208–2216.
[53] H. Chikumi, S. Fukuhara, J.S. Gutkind, Regulation of G protein-linked guanine
nucleotide exchange factors for Rho, PDZ-RhoGEF, and LARG by tyrosine phos-
phorylation: evidence of a role for focal adhesion kinase, J. Biol. Chem. 277 (2002)
12463–12473.
[54] H. Ogita, S. Kunimoto, Y. Kamioka, H. Sawa, M. Masuda, N. Mochizuki, EphA4-
mediated Rho activation via Vsm-RhoGEF expressed speciﬁcally in vascular smooth
muscle cells, Circ Res. 93 (2003) 23–31.
[55] N. Suzuki, S. Nakamura, H. Mano, T. Kozasa, Galpha 12 activates Rho GTPase
through tyrosine-phosphorylated leukemia-associated RhoGEF, Proc. Natl. Acad.
Sci. USA 100 (2003) 733–738.
[56] B.H. Meyer, F. Freuler, D. Guerini, S. Siehler, Reversible translocation of p115-
RhoGEF by G(12/13)-coupled receptors, J. Cell Biochem. 104 (2008) 1660–1670.
[57] M. Hirakawa, M. Oike, Y. Karashima, Y. Ito, Sequential activation of RhoA and
FAK/paxillin leads to ATP release and actin reorganization in human endothelium,
J. Physiol. 558 (2004) 479–488.
[58] K. Takaishi, T. Sasaki, T. Kameyama, S. Tsukita, S. Tsukita, Y. Takai, Translocation
of activated Rho from the cytoplasm to membrane ruﬄing area, cell-cell adhesion
sites and cleavage furrows, Oncogene 11 (1995) 39–48.
[59] K. Abe, K.L. Rossman, B. Liu, K.D. Ritola, D. Chiang, S.L. Campbell, et al., Vav2 is an
activator of Cdc42, Rac1, and RhoA, J. Biol. Chem. 275 (2000) 10141–10149.
[60] J.M. Servitja, M.J. Marinissen, A. Sodhi, X.R. Bustelo, J.S. Gutkind, Rac1 function is
required for Src-induced transformation. Evidence of a role for Tiam1 and Vav2 in
Rac activation by Src, J. Biol. Chem. 278 (2003) 34339–34346.
[61] J. Andreev, M.L. Galisteo, O. Kranenburg, S.K. Logan, E.S. Chiu, M. Okigaki, et al.,
Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth
factor receptor (EGFR) but are not required for coupling to the mitogen-activated
protein (MAP) kinase signaling cascade, J. Biol. Chem. 276 (2001) 20130–20135.
[62] M.B. Calalb, T.R. Polte, S.K. Hanks, Tyrosine phosphorylation of focal adhesion
kinase at sites in the catalytic domain regulates kinase activity: a role for Src family
kinases, Mol Cell Biol. 15 (1995) 954–963.
[63] G.B. Daou, A.K. Srivastava, Reactive oxygen species mediate Endothelin-1-induced
activation of ERK1/2, PKB, and Pyk2 signaling, as well as protein synthesis, in
vascular smooth muscle cells, Free Radic. Biol. Med. 37 (2004) 208–215.
[64] N.K. Singh, D. Wang, V. Kundumani-Sridharan, Q.D. Van, J. Niu, G.N. Rao, 15-
Lipoxygenase-1-enhanced Src-Janus kinase 2-signal transducer and activator of
transcription 3 stimulation and monocyte chemoattractant protein-1 expression
require redox-sensitive activation of epidermal growth factor receptor in vascular
wall remodeling, J. Biol. Chem. 286 (2011) 22478–22488.
[65] S. Vepa, W.M. Scribner, N.L. Parinandi, D. English, J.G. Garcia, V. Natarajan,
Hydrogen peroxide stimulates tyrosine phosphorylation of focal adhesion kinase in
vascular endothelial cells, Am. J. Physiol. 277 (1999) L150–L158.
[66] R. Gadepalli, N.K. Singh, V. Kundumani-Sridharan, M.R. Heckle, G.N. Rao, Novel
role of proline-rich nonreceptor tyrosine kinase 2 in vascular wall remodeling after
balloon injury, Arterioscler. Thromb. Vasc. Biol. 32 (2012) 2652–2661.
[67] Y. Lim, S.T. Lim, A. Tomar, M. Gardel, J.A. Bernard-Triﬁlo, X.L. Chen, et al., PyK2
and FAK connections to p190Rho guanine nucleotide exchange factor regulate
RhoA activity, focal adhesion formation, and cell motility, J. Cell Biol. 180 (2008)
187–203.
C.E. MacKay et al. Free Radical Biology and Medicine 110 (2017) 316–331
331
